HyTest Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
HyTest Ltd. - overview
Established
1994
Location
Turku, -, Finland
Primary Industry
Biotechnology
About
Based in Turku, Finland, and founded in 1994, HyTest Ltd. develops and supplies immunological reagents for the IVD industry and research community. In September 2018, Summa Equity acquired a majority stake in HyTest Ltd. and in May 2021, Shenzhen Mindray Bio-Medical Electronics Co.
, Ltd. acquired HyTest Ltd. for approximately EUR 545 million. As of 2024, the company is led by its CEO, Netta (Fatal) Keinänen.
The company’s product category for the IVD industry includes monoclonal antibodies, polyclonal antibodies, sera, plasma, and antigens. The company’s clinical area-based products include cardiac markers, blood coagulation and anaemia, metabolic syndrome, kidney diseases, fertility and pregnancy, hormones, tumor markers, neuroscience, immunology and serology, inflammation, infectious diseases, veterinary, microbial, and plant toxins, biodefense, miscellaneous, and gangliosides.
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals
Website
www.hytest.fi/
Company Stage
Acquired
Total Amount Raised
Subscriber access only
HyTest Ltd. - timeline of key events
HyTest Ltd. - financials
| Fiscal Year Ended | Oct 31, 2009 | Oct 31, 2010 | Oct 31, 2011 | Oct 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 7,777,929.5 | 9,092,117.1 | 10,205,762.3 | 12,731,505.7 | 15,375,343.2 | 16,255,150.8 | 17,316,843.8 | 23,776,949.2 | 24,089,774.2 | 22,284,819 | 24,730,629.2 | 26,617,556.8 | 32,531,988.7 | - | - | - |
| % Revenue Growth (YoY) | - | 16.9% | 12.2% | 24.7% | - | - | 6.5% | 37.3% | 1.3% | (7.5%) | 11.0% | 7.6% | 22.2% | - | - | - |
| EBITDA (USD) | 2,281,864.9 | 3,118,835.7 | 3,780,753.7 | 4,765,351.8 | 6,487,848.6 | 6,713,804 | 7,313,673 | 11,463,463.9 | 11,610,052.3 | 6,544,326 | 11,081,735.2 | 10,831,187 | 17,046,819.3 | - | - | - |
| Operating Income (USD) | 2,242,849.5 | 3,083,007.1 | 3,746,196 | 4,727,681.1 | 6,431,655.9 | 6,625,325.3 | 7,215,012.7 | 11,265,722.4 | 11,405,516.7 | 6,367,566 | 10,913,797.9 | 10,737,593 | 16,964,600.7 | - | - | - |
| Operating Margin | 28.8% | 33.9% | 36.7% | 37.1% | 41.8% | 40.8% | 41.7% | 47.4% | 47.3% | 28.6% | 44.1% | 40.3% | 52.1% | - | - | - |
| % EBITDA Margin | 29.3% | 34.3% | 37.0% | 37.4% | 42.2% | 41.3% | 42.2% | 48.2% | 48.2% | 29.4% | 44.8% | 40.7% | 52.4% | - | - | - |
| NET Income (USD) | 1,644,914.9 | 2,285,255.5 | 2,773,452.7 | 3,728,837 | 4,946,384.9 | 5,255,583.9 | 5,813,107.6 | 9,086,409.6 | 8,985,845.5 | 5,193,491.1 | - | 3,356,822.3 | 2,094,262.2 | - | - | - |
| % Net Margin | 21.1% | 25.1% | 27.2% | 29.3% | 32.2% | 32.3% | 33.6% | 38.2% | 37.3% | 23.3% | - | 12.6% | 6.4% | - | - | - |
HyTest Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Sale | Completed | HyTest Ltd. | - | ||||||||
| Buyout | Completed | HyTest Ltd. | - |
Displaying 1 - 2 of 2
HyTest Ltd. - employee data
HyTest Ltd. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Member of Board of Directors | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.